Primary Membranoproliferative Glomerulonephritis

Watchlist

(log in to enable)

Retrieved

2021-01-23

Source

Orphanet

Trials

—

Genes

CFH, TSLP, ALB, CFB, PON1, DNASE2, C1QA, FN1, EP300, PFN1, IL1B, TGFBR2, CCL2, F5, SPARC, EDN1, MYOC, CCN2, CCR6, CDKN1B, CDK2, PRF1, ANGPT2, CXCR1, LMNB2, SOX18, PGM3, IGAN1, IL6, C3

CFH, TSLP, ALB, CFB, PON1, DNASE2, C1QA, FN1, EP300, PFN1, IL1B, TGFBR2, CCL2, F5, SPARC, EDN1, MYOC, CCN2, CCR6, CDKN1B, CDK2, PRF1, ANGPT2, CXCR1, LMNB2, SOX18, PGM3, IGAN1, IL6, C3, VWF, CFHR3, ADAMTS13, VTN, VEGFA, THY1, TLR9, CFHR5, TAGLN, AFP, MPO, RIT2, PTEN, PIK3CG, PIK3CD, PIK3CB, PIK3CA, AKT1, MMP9, IGHG3, HRAS, HLA-DRB1, HLA-DQB1, CFHR1, CSF3, CGA, RBM45

Drugs

(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamide, 4-{(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl}benzoic acid-hydrogen chloride(1/1), Avacopan, PEGylated peptide inhibitor of complement C3, Recombinant human minibody against complement component C5, S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)

Interested in hearing about new therapies?

Membranoproliferative glomerulonephritis (MPGN) is a chronic progressive kidney disorder characterized by glomerular capillary wall structural changes and mesangial cell proliferation leading to nephrotic syndrome, hypocomplementemia, hypertension, proteinuria and end-stage kidney disease. MPGN can be due to either idiopathic (type 1, 2 and 3 MPGN; see these terms) or secondary (associated with infectious and immune complex diseases) causes.